Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Analysts

Key Points

• Analysts give Organon a consensus rating of Reduce from seven firms (4 sell, 2 hold, 1 strong buy), with an average 12‑month price target of $8.50.
• Organon missed Q4 estimates (EPS $0.63 vs. $0.73; revenue $1.51B vs. $1.52B) and the stock trades around $9.28 with a market cap of $2.42B, P/E of 13.07 and a 52‑week range of $5.69–$13.24.

Organon & Co. (NYSE:OGN - Get Free Report) has received a consensus rating of "Reduce" from the seven research firms that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.50.

A number of research firms have weighed in on OGN. Barclays increased their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 24th. Wall Street Zen downgraded shares of Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Finally, Zacks Research raised shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently made changes to their positions in OGN. AQR Capital Management LLC raised its stake in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company's stock valued at $61,282,000 after acquiring an additional 4,394,814 shares during the period. Vanguard Group Inc. raised its stake in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company's stock valued at $383,715,000 after acquiring an additional 3,650,860 shares during the period. UBS Group AG raised its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company's stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the period. Private Management Group Inc. raised its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock valued at $31,169,000 after acquiring an additional 1,204,979 shares during the period. Finally, Balyasny Asset Management L.P. raised its stake in shares of Organon & Co. by 102.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company's stock valued at $23,925,000 after acquiring an additional 1,131,941 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Performance

NYSE:OGN opened at $9.28 on Tuesday. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. The company has a market cap of $2.42 billion, a P/E ratio of 13.07, a P/E/G ratio of 0.90 and a beta of 0.67. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.24. The firm's 50 day moving average is $7.06 and its two-hundred day moving average is $7.67.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $0.73 by ($0.10). The company had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.52 billion. Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business's revenue for the quarter was down 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.90 EPS. Analysts expect that Organon & Co. will post 3.24 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Monday, February 23rd. Organon & Co.'s dividend payout ratio (DPR) is currently 11.27%.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.